Sudhir Agrawal

Q: What Schools Are Affiliated With Sudhir Agrawal

Sudhir Agrawal is affiliated with the following schools: University of Alabama at Birmingham, University of Alabama, California Institute of Technology, University of Verona, Stanford University, Georgetown University, University of Massachusetts Medical School, University of North Carolina at Chapel Hill

Sudhir Agrawal's AcademicInfluence.com Rankings

Sudhir Agrawal

Computer Science

#6571

World Rank

#6928

Historical Rank

Machine Learning

#2182

World Rank

#2210

Historical Rank

Artificial Intelligence

#2448

World Rank

#2489

Historical Rank

Database

#3657

World Rank

#3808

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Sudhir Agrawal's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University

Similar Degrees You Can Earn

Why Is Sudhir Agrawal Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sudhir Agrawal's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. (1991) (518)
Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer. (1988) (427)
Antisense Research and Applications (1993) (381)
Antisense oligonucleotides: towards clinical trials. (1996) (258)
MDM2 Is a Negative Regulator of p21WAF1/CIP1, Independent of p53* (2004) (253)
Pharmacokinetics of Antisense Oligonucleotides (1995) (251)
Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. (1996) (234)
Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides (1999) (224)
Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. (1997) (220)
Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. (1994) (212)
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy (2003) (198)
In vivo studies with antisense oligonucleotides. (1997) (189)
Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. (1999) (187)
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics (2004) (178)
Effect of different chemically modified oligodeoxynucleotides on immune stimulation. (1996) (170)
Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. (1998) (169)
Efficient methods for attaching non-radioactive labels to the 5' ends of synthetic oligodeoxyribonucleotides. (1986) (163)
Antisense therapeutics: is it as simple as complementary base recognition? (2000) (145)
Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. (1995) (134)
Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis (2006) (134)
Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway (2005) (129)
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. (1995) (128)
Survivin inhibition induces human neural tumor cell death through caspase‐independent and ‐dependent pathways (2001) (125)
Synthetic agonists of Toll-like receptors 7, 8 and 9. (2007) (124)
Dual Blockade of Cyclic AMP Response Element- (CRE) and AP-1-directed Transcription by CRE-transcription Factor Decoy Oligonucleotide (1999) (124)
Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. (1999) (124)
Antisense oligonucleotides as antiviral agents. (1992) (123)
Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV‐infected subjects (1995) (119)
Protocols for Oligonucleotides and Analogs (1993) (117)
Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. (2001) (110)
Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. (1997) (107)
Antisense and siRNA as agonists of Toll-like receptors (2004) (103)
Thermal stress-induced HSP70 mediates protection against intrapancreatic trypsinogen activation and acute pancreatitis in rats. (2002) (102)
Modified oligonucleotides as therapeutic and diagnostic agents. (1995) (93)
In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. (1995) (90)
Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. (2005) (90)
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines (2001) (89)
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms (2003) (88)
Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity. (1993) (87)
MDM2 oncogene as a target for cancer therapy: An antisense approach. (1999) (87)
Heat shock protein 70 prevents secretagogue-induced cell injury in the pancreas by preventing intracellular trypsinogen activation. (2000) (86)
Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression (1999) (85)
Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity. (2002) (85)
Sequence identity of the n-1 product of a synthetic oligonucleotide. (1995) (83)
Antisense and/or immunostimulatory oligonucleotide therapeutics. (2001) (79)
Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. (1998) (79)
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. (1998) (78)
Medicinal chemistry and therapeutic potential of CpG DNA. (2002) (78)
Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors (2006) (77)
Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. (1994) (77)
Stabilization of the MDM2 Oncoprotein by Mutant p53* (2001) (75)
GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. (1992) (74)
Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8 (2007) (74)
Oligodeoxynucleoside methylphosphonates: synthesis and enzymic degradation (1987) (73)
'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. (2002) (72)
Protocols for oligonucleotides and analogs : synthesis and properties (1993) (71)
Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery. (1995) (71)
Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. (2000) (70)
Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties. (2000) (70)
Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/ GEM®640 (2005) (68)
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. (1999) (68)
Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. (2005) (68)
Chemotherapy and chemosensitization of non–small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9 (2006) (67)
A novel MDM2 anti‐sense oligonucleotide has anti‐tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer (2000) (67)
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts (2007) (65)
A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. (2013) (64)
Perspectives in antisense therapeutics. (1997) (63)
Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. (2001) (63)
TLR9 Agonist Protects Mice from Radiation-Induced Gastrointestinal Syndrome (2012) (62)
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. (2003) (62)
A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice (2013) (62)
Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models (2004) (61)
Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-o- methyloligoribonucleotides (1994) (60)
An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy (2012) (60)
Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9 (2013) (59)
Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. (2002) (59)
Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. (2009) (58)
A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif (2003) (58)
Protocols for Oligonucleotide Conjugates (1993) (57)
Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice. (1993) (56)
Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. (2014) (55)
Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. (2007) (55)
Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments. (1997) (55)
Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. (2018) (54)
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. (1997) (54)
Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. (1996) (53)
Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti‐MDM2 Oligonucleotides (2003) (53)
Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. (1999) (52)
Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates. (1994) (50)
Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers (2011) (49)
In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. (1997) (48)
Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms (2002) (47)
In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. (1995) (47)
Effects of synthetic oligonucleotides on human complement and coagulation. (1997) (46)
Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9 (2009) (46)
Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. (2002) (45)
EGF‐related peptides are involved in the proliferation and survival of MDA‐MB‐468 human breast carcinoma cells (1999) (45)
Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. (1997) (45)
Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer (2004) (44)
Analytical study of phosphorothioate analogues of oligodeoxynucleotides using high-performance liquid chromatography. (1990) (43)
Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. (1998) (43)
Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. (2009) (43)
Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. (2000) (42)
Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs. (2003) (42)
Modulation of Toll‐like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA (2003) (42)
Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice. (1998) (41)
Solid-phase stereoselective synthesis of oligonucleoside phosphorothioates: The nucleoside bicyclic oxazaphospholidines as novel synthons (1998) (41)
Ion-exchange high-performance liquid chromatography analysis of oligodeoxyribonucleotide phosphorothioates. (1992) (41)
A NOVEL NUCLEOSIDE PHOSPHORAMIDITE SYNTHON DERIVED FROM 1R,2S-EPHEDRINE (1995) (41)
RAGE Enhances TLR Responses through Binding and Internalization of RNA (2016) (40)
Secondary structures in CpG oligonucleotides affect immunostimulatory activity. (2003) (38)
Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. (2003) (38)
Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy (2006) (37)
Role of Toll-like receptors in antisense and siRNA [corrected]. (2004) (37)
In situ hybridization histochemistry: localisation of vasopressin mRNA in rat brain using a biotinylated oligonucleotide probe. (1988) (37)
Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-Like Receptors 7 and 8 (2010) (37)
MDM 2 Is a Negative Regulator of p 21 WAF 1 / CIP 1 , Independent of p 53 * (2004) (37)
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action (2009) (36)
EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. (2000) (35)
Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. (2001) (35)
Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. (2004) (35)
Prodrugs of Oligonucleotides: The Acyloxyalkyl Esters of Oligodeoxyribonucleoside Phosphorothioates (1995) (34)
Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity. (2010) (33)
Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. (1998) (33)
Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. (2002) (32)
Site specific functionalization of oligonucleotides for attaching two different reporter groups. (1990) (32)
Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. (2004) (32)
Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis. (2017) (32)
CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. (2003) (31)
Pharmacokinetics of oligonucleotides. (2007) (31)
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. (2007) (31)
Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RIα subunit: p53-independent mechanism of action (1999) (31)
Cutting Edge: The UNC93B1 Tyrosine-Based Motif Regulates Trafficking and TLR Responses via Separate Mechanisms (2014) (31)
Protocols for oligonucleotide conjugates : synthesis and analytical techniques (1994) (31)
Effect of G-rich sequences on the synthesis, purification, hybridization, cell uptake, and hemolytic activity of oligonucleotides (1996) (31)
Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. (2005) (30)
CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. (2004) (30)
Towards optimal design of second-generation immunomodulatory oligonucleotides. (2002) (30)
Antisense therapeutics. (1998) (30)
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. (2002) (30)
In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. (1997) (29)
Incompatibility of acid-labile 2′ and 5′ protecting groups for solid-phase synthesis of oligoribonucleotides (1986) (29)
Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. (2003) (29)
Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. (2002) (29)
Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H. (1998) (28)
Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. (2003) (28)
Efficient synthesis of oligoribonucleotide and its phosphorothioate analogue using H-phosphonate approach (1990) (28)
'Cyclicons' as hybridization-based fluorescent primer-probes: synthesis, properties and application in real-time PCR. (2000) (27)
Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages. (2002) (27)
Single strand targeted triplex formation: parallel-stranded DNA hairpin duplexes for targeting pyrimidine strands (1995) (27)
Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats. (1998) (26)
Enzymatic Synthesis of Stereoregular (All Rp) Oligonucleotide Phosphorothioate and Its Properties (1995) (26)
Novel MDM2 p53‐Independent Functions Identified through RNA Silencing Technologies (2005) (26)
Hoogsteen DNA duplexes of 3'-3'- and 5'-5'-linked oligonucleotides and trip formation with RNA and DNA pyrimidine single strands: experimental and molecular modeling studies. (1996) (26)
Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. (2002) (25)
Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides. (1995) (25)
Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. (1999) (25)
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. (2002) (24)
Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies. (2009) (24)
Single-strand-targeted triplex formation: stability, specificity and RNase H activation properties. (1994) (24)
Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo (2008) (23)
A rapid method for quantitation of oligodeoxynucleotide phosphorothioates in biological fluids and tissues. (1993) (23)
Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs. (2007) (23)
Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8. (2009) (23)
Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI a subunit of protein kinase A after oral administration (1999) (23)
Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity. (1996) (23)
PKA knockdown enhances cell killing in response to radiation and androgen deprivation (2011) (22)
Biotinylated antisense methylphosphonate oligodeoxynucleotides. Inhibition of spliceosome assembly and affinity selection of U1 and U2 small nuclear RNPs. (1991) (22)
Was Induction of HIV-1 Through TLR9? (2003) (22)
Stereospecific bio-reversibility of dinucleoside S-alkyl phosphorothiolates to dinucleoside phosphorothioates (1994) (22)
Effect of 2'-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells. (2001) (22)
NMR structure of a 2',5' RNA favors A type duplex with compact C2'endo nucleotide repeat. (2001) (21)
Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals (1998) (21)
Single strand targeted triplex-formation. Destabilization of guanine quadruplex structures by foldback triplex-forming oligonucleotides. (1995) (21)
Biodistribution and metabolism of a mixed backbone oligonucleotide (GEM 231) following single and multiple dose administration in mice. (2000) (20)
Acyloxyaryl prodrugs of oligonucleoside phosphorothioates (1996) (20)
Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. (2009) (20)
Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. (2001) (20)
Impact of Secondary Structure of Toll-Like Receptor 9 Agonists on Interferon Alpha Induction (2008) (19)
Phosphoramidate, Phosphorothioate, and Methylphosphonate Analogs of Oligodeoxynucleotide : Inhibitors of Replication of Human Immunodeficiency Virus (1989) (19)
Synthesis of Iodoalkylacylates and Their Use in the preparation of S-Alkyl Phosphorothiolates (1995) (19)
A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. (2003) (19)
Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. (2002) (19)
Capped Oligodeoxynucleotide Phosphorothioates. (1992) (19)
O- and S-Methyl Phosphotriester Oligonucleotides: Facile Synthesis Using N-Pent-4-enoyl Nucleoside Phosphoramidites (1995) (19)
Novel enzymatic and immunological responses to oligonucleotides. (1995) (19)
Advances in antisense efficacy and delivery. (1995) (18)
Solid-phase stereoselective synthesis of 2'-O-methyl-oligoribonucleoside phosphorothioates using nucleoside bicyclic oxazaphospholidines. (1998) (18)
Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice. (2005) (18)
Antisense oligonucleotides as modulators of pre-mRNA splicing. (2000) (18)
Antisense depletion of RIα subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells (1998) (18)
Enzymatic labeling of nucleic acids (1996) (18)
Antisense oligonucleotides: gene regulation and chemotherapy of AIDS (1991) (18)
The Cockayne syndrome group B DNA repair protein as an anti-cancer target. (2001) (17)
Functionalization of oligonucleotides with amino groups and attachment of amino specific reporter groups. (1994) (17)
Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. (1996) (17)
Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors (2005) (16)
Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. (2004) (16)
Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494 (2017) (16)
A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. (2010) (16)
Novel oligonucleotides containing two 3'-ends complementary to target mRNA show optimal gene-silencing activity. (2011) (16)
Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. (2021) (16)
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis (2013) (15)
Modulation of the PC12 cell response to nerve growth factor by antisense oligonucleotide to amyloid precursor protein (1994) (15)
Cell binding, uptake and cytosolic partition of HIV anti-gag phosphodiester oligonucleotides 3'-linked to cholesterol derivatives in macrophages. (1999) (15)
Synergistic activation of p 53 by inhibition of MDM 2 expression and DNA damage (1997) (14)
Synthesis and immunological activities of novel agonists of toll-like receptor 9. (2010) (14)
Single stand targeted triplex formation: physicochemical and biochemical properties of foldback triplexes. (1996) (14)
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides. (2001) (14)
Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications (2006) (14)
N-pent-4-enoyl (PNT) group as a universal nucleobase protector: Applications in the rapid and facile synthesis of oligonucleotides, analogs, and conjugates (1997) (14)
Bioreversible oligonucleotide conjugates by site-specific derivatization (1997) (14)
Restoration of ß-Globin Gene Expression in Mammalian Cells by Antisense Oligonucleotides That Modify the Aberrant Splicing Patierns of Thalassemic Pre-mRNAs (1997) (13)
Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors (2019) (13)
On the quality control of antisense oligonucleotides. (1996) (13)
Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation. (1998) (13)
Improved Procedure for the Reduction of N - 1 Content in Synthetic Oligonucleotides (1995) (12)
Effect on embryos of injection of phosphorothioate-modified oligonucleotides into pregnant mice. (1993) (12)
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. (1998) (12)
Oligonucleotides Containing Acyclic Nucleoside Analogues with Carbamate Internucleoside Linkages (1995) (12)
Diethoxy N, N-diisopropyl phosphoramidite as an improved capping reagent in the synthesis of oligonucleotides using phosphoramidite chemistry (1994) (11)
N-pent-4-enoyl nucleosides: Application in the synthesis of support-bound and free oligonucleotide analogs by the H-phosphonate approach (1996) (11)
Nucleoside Oxazaphospholidines as Novel Synthons in Oligonucleotide Synthesis (1995) (11)
Antisense MDM2 Enhances E2F1-Induced Apoptosis and the Combination Sensitizes Androgen-Dependent and Androgen-Independent Prostate Cancer Cells to Radiation (2008) (11)
Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8. (2009) (11)
Uptake, intracellular distribution, and stability of oligodeoxynucleotide phosphorothioate by Schistosoma mansoni. (1995) (11)
Synthesis and Anti‐HIV Activity of Oligoribonucleotides and Their Phosphorothioate Analogs (1992) (11)
Synthesis of oligodeoxynucleoside methylphosphonothioates (1993) (11)
IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice (119.12) (2012) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Synthesis of di-, tri-, and tetrameric building blocks with novel carbamate internucleoside linkages and their incorporation into oligonucleotides (1994) (10)
Synthesis of [35S]3H-1,2-benzodithiole-3-one-1,1-dioxide: Application in the Preparation of site-specifically 35S-labeled oligonucleotides (1994) (10)
3′-3′-linked oligonucleotides: Synthesis and stability studies (1996) (10)
Nonradioactive methods of in situ hybridization: visualization of neuroendocrine mRNA. (1989) (10)
Single strand targeted triplex formation: targeting purine-pyrimidine mixed sequences using abasic linkers. (1995) (10)
Immune Modulatory Oligonucleotides in Prevention of Nasal Allergen—Induced Eustachian Tube Dysfunction in Rats (2007) (10)
Oligonucleoside phosphoramidates from N-pent-4-enoyl nucleoside H-phosphonates (1996) (10)
Induction of immune activation by a novel immunomodulatory oligonucleotide without thymocyte apoptosis. (2004) (9)
The use of gaseous ammonia for the deprotection and cleavage steps during the solid-phase synthesis of oligonucleotides, and analogs (1997) (9)
Pseudo-cyclic oligonucleotides: in vitro and in vivo properties. (1999) (9)
Synthesis, biophysical properties, and stability studies of mixed backbone oligonucleotides containing segments of methylphosphotriester internucleotidic linkages (1996) (9)
An efficient synthesis of radioisotopically labeled oligonucleotides through direct solid-phase 5′-phosphitylation (1995) (9)
Preparation of functionalized oligonucleoside methylphosphonate suitable for non-radioactive label attachment (1989) (9)
IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in mouse models of psoriasis (119.8) (2012) (9)
Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia (2015) (9)
Improved Procedure for the Detritylation of DMT-Oligonucleotides: Use of Dowex® (1995) (8)
A New 5′-Protecting Group for Use in Solid-Phase Synthesis of Oligoribonucleotides (1987) (8)
Mixed-Backbone Oligonucleotides Containing Phosphorothioate and Methylphosphonate Linkages as Second Generation Antisense Oligonucleotide (1997) (8)
Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation (2014) (8)
Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation (2004) (8)
Mixed backbone oligonucleotides containing internucleotidic primary phosphoramidate linkages (1996) (8)
The Evolution of Antisense Oligonucleotide Chemistry—A Personal Journey (2021) (8)
The role of immunomodulatory oligonucleotides in prevention of OVA-induced Eustachian tube dysfunction. (2006) (8)
Immune Modulatory Oligonucleotides in the Prevention and Treatment of OVA-Induced Eustachian Tube Dysfunction in Rats (2007) (8)
Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists. (2011) (8)
A mild and efficient solid-support synthesis of novel oligonucleotide conjugates. (1998) (8)
Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses. (2013) (7)
Repair of thalassemic human b-globin mRNA in mammalian cells by antisense oligonucleotides ( RNA splicing y gene therapy ) (1996) (7)
Single-stranded DNA and RNA targeted triplex-formation: UV, CD and molecular modeling studies of foldback triplexes containing different RNA, 2'-OMe-RNA and DNA strand combinations. (1997) (7)
Agonists of Toll-Like Receptor 9 (2005) (7)
IMO-3100, an Antagonist of Toll-Like Receptors 7 and 9, Modulates Gene Expression and Regulatory Networks Induced by Ligands (48.25) (2009) (7)
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling (1990) (7)
Antisense Anti-MDM 2 Oligonucleotides As a Novel Therapeutic Approach to Human Breast Cancer : In Vitro and in Vivo Activities and Mechanisms 1 (2001) (7)
Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive and androgen-insensitive prostate cancer cells to radiation (Molecular Cancer Research (2008) 6, (1742-1754)) (2008) (6)
Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice. (2006) (6)
RNA Therapeutics Are Stepping Out of the Maze (2020) (6)
A phase I study of HYB2055 in patients (pts) with advanced solid malignancies. (2004) (6)
SYNTHESIS AND PROPERTIES OF 2'-O-METHYLRIBONUCLEOTIDE METHYLPHOSPHONATE CONTAINING CHIMERIC OLIGONUCLEOTIDES (1995) (6)
Method for sequencing synthetic oligodeoxynucleotide phosphorothioates. (1993) (6)
Repression of human thymidylate synthase mRNA translation by antisense 2'-O-methyl oligoribonucleotides. (1998) (6)
Comparative pharmacokinetics of antisense oligonucleotides. (1996) (6)
Intratumoral pharmacokinetics of oligonucleotides in a tissue-isolated tumor perfusion system. (2000) (5)
Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides (2011) (5)
Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM). (2017) (5)
Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo. (2013) (5)
Site-specific synthesis of [3H]oligonucleotides in high specific activity through direct solid-phase redox chemistry (1995) (5)
Patent strategies in the antisense oligonucleotide based therapeutic approach (1997) (4)
Sequencing of synthetic oligonucleotides and analogs by homopolymeric tailing. (1995) (4)
Antisense depletion of RIalpha subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells. (1998) (4)
Single strand targeted triplex formation: strand displacement of duplex DNA by foldback triplex-forming oligonucleotides. (1995) (4)
Therapeutic potential of synthetic CpG DNA--current status and future directions. (2001) (4)
Inhibition of in vitro transcription by oligodeoxynucleotides. (1994) (4)
Sa1757 Targeting Innate Immune Receptors to Treat Inflammatory Bowel Disease: Preclinical Activity of IMO-9200, an Antagonist of TLRS 7, 8, and 9 in Mouse Models of Colitis (2015) (4)
Abstract B094: Intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates the tumor microenvironment and exerts systemic antitumor activity alone and in combination with an anti-CTLA-4 mAb (2016) (4)
CHAPTER 1. History and Development of Nucleotide Analogues in Nucleic Acids Drugs (2019) (4)
Abstract B196: Intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates tumor microenvironment and potentiates antitumor activity of anti-PD-1 mAb in a murine colon carcinoma model (2015) (4)
New molecular targets for anticancer therapy (1998) (3)
Destabilization of DNA Guanine Quadruplex Structure by Foldback Triplex-Forming Oligodeoxynucleotides (1995) (3)
IMO-4200, a Novel TLR7 and TLR8 Dual Agonist, Enhances Antitumor Effect of Ofatumumab, Rituximab and Cytotoxics in Preclinical Models of Hematological Malignancies, (2011) (3)
Hybridization-based fluorescence assay allows quantitation of single-stranded oligodeoxynucleotides in low nanomolar range. (2004) (3)
A phase I study of HYB2055 in patients (pts) with advanced solid malignancies (2004) (3)
Abstract 5652: Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma (2017) (3)
Cooperative inhibition of human renal cancer cell growth by treatment with anti-epidermal growth factor receptor monoclonal antibody and a mixed backbone antisense oligonucleotide targeting type I protein kinase A (1998) (3)
Solid phase synthesis of oligonucleotides carrying puromycin at 3′-terminal (1993) (3)
Abstract B159: Modulation of checkpoint expression in tumor microenvironment by intratumoral administration of a novel TLR9 agonist: Rationale for combination therapy (2016) (3)
Incorporation of multiple reporter groups on synthetic oligonucleotides. (1990) (3)
Loquatoside - a new leucocyanin from Eriobotrya japonica fruits. (1980) (2)
Supra-additive effect of IMO-4200, a novel TLR7 and TLR8 dual agonist, with rituximab and cytotoxics in preclinical models of hematologic malignancies. (2011) (2)
Protein kinase a riα antisense sensitization of radiation and androgen deprivation (2004) (2)
Synthesis, Biophysical Properties, and Stability Studies of Mixed Backbone Oligonucleotides Containing Novel Non-Ionic Linkages (1997) (2)
Abstract 3847: Creating the tumor microenvironment for effective immunotherapy: Antitumor activity of intratumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO) (2016) (2)
Dollars and Antisense (1997) (2)
Blocking Toll-Like Receptor Pathway Using an Antagonist of TLR7, 8 and 9 Reduces Inflammation in Dystrophin Deficient mdx Mice (PD3.004) (2013) (1)
Antisense Oligonucleotide-Based Therapy for HIV-1 Infection from Laboratory to Clinical Trials (2020) (1)
Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts (2007) (1)
8 – Nonradioactive Methods of in Situ Hybridization: Visualization of Neuroendocrine mRNA (1989) (1)
New molecular targets for anticancer therapy. The First International Conference on New Molecular Targets for Anticancer Therapy. Naples, Italy. June 22-23 1998. (1998) (1)
Introduction and History of the Chemistry of Nucleic Acids Therapeutics (2022) (1)
Down-regulation of Th2 cytokines in vitro by immunomodulatory oligonucleotides (IMO) containing modified CpG motifs (2003) (1)
Impact of Site-Specific Nucleobase Deletions on the Arthritogenicity of DNA (2004) (1)
Oral administration of chimeric MBO antisense-protein kinase A inhibits growth, angiogenesis and growth factors production and cooperates with cytotoxic drugs in human cancer xenografts (1999) (1)
Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models (2022) (1)
Abstract 4704: Triple combination of IMO-2125, epacadostat and anti-PD-1 antibody demonstrates maximal antitumor efficacy and eradicates large established tumors in preclinical models (2018) (1)
Use of Drugs Targeted to Inhibit Different Stages of the HIV Life Cycle in the Treatment of AIDS (1992) (1)
HSP70 Antisense oligonucleotide administration prevents the thermal stress-induced expression of HSP70 in rat pancreas and abolishes the thermal stress-induced protection against caerulein-induced pancreatitis (2001) (1)
Synthesis, purification, and characterization of 2,4,6-trinitrophenyl-UDP-galactose: a fluorescent substrate for galactosyltransferase. (1990) (1)
Antitumor Activity of An RNA-Based Agonist of TLR7 and 8 In Preclinical Models of Hematological Malignancies (2010) (1)
Corrigenda: Antisense and siRNA as agonists of Toll-like receptors (2005) (1)
Antitumor activity of IMO-2055, an agonist of TLR9, in combination with erlotinib and bevacizumab in non-small cell lung cancer xenografts in mice (2008) (1)
CHAPTER 14. Synthetic Agonists of Toll-like Receptors and Therapeutic Applications (2019) (1)
Mixed-Backbone Oligonucleotides Containing Segments of Deoxynucleosides Phosphorothioate and 2'-O-Methylribonucleosides Methylphosphonate: Synthesis and Properties (1999) (1)
Improved Procedure for the Detritylation of DMT-Oligonucleotides: Use of Dowex. (1996) (0)
A Novel Nucleoside Phosphoramidite Synthon Derived from (1R,2S)‐ Ephedrine. (1995) (0)
Patent Number : 45 ) Date of Patent : 5 , 541 , 306 Jul . 30 , 1996 (2017) (0)
Incompatibility of Acid-Labile 2′ and 5′ Protecting Groups for Solid- Phase Synthesis of Oligoribonucleotides. (1986) (0)
A therapeutic anti-HIV drug and oligonukletid (1993) (0)
Method for site-specific modification of rna and production of polypeptides encoded thereby (1991) (0)
Antiangiogenic and antitumor effect of VEGF antisense oligonucleotide in combination with anti-EGFR C225 monoclonal antibody in human colon cancer (1999) (0)
A method for sequencing synthetic oligonucleotides containing internucleotide linkages, which are not of the phosphodiester-type (1993) (0)
Abstract 11182: Novel Tlr7 and Tlr9 Dual Antagonist Lowers Cholesterol in Hyperlipidemic Mice Through Il-10-Mediated Activation of Lxr and Increased Fecal Neutral Sterol Loss (2010) (0)
1000 A novel drug Toll-like receptor 9 (TLR9) agonist synergizes with trastuzumab in different trastuzumab-resistant breast tumours via multiple mechanisms of action (2009) (0)
Su.42. Oligoribonucleotides Containing Arabinonucleosides Act as Potent Agonists of Toll-like Receptors 7 and 8 (2008) (0)
Oral antisense targeting protein kinase A type I causes antitumor and apoptotic effect in human cancer cells in vitro and in vivo and has cooperative activity in combination with antisense bcl-2. (1999) (0)
Complement activation following intravenous administration of ollgonucleotide phosphorothloate in the monkey (1994) (0)
Chemistry of CpG DNA (2003) (0)
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts (2005) (0)
692 IMO-2125, AN AGONIST OF TLR9, THAT INDUCES ENDOGENOUS IFN-α UPREGULATES BROADER RANGE OF GENE EXPRESSION PROFILES COMPARED TO EXOGENOUSLY ADDED IFN-α IN HUMAN PBMCS (2010) (0)
TLR9 agonist second-generation immunomodulatory oligonucleotides reverse OVA-triggered Th2 responses in mice (2005) (0)
Immunomodulatory compounds stabilized RNA (Simra) TLR8 and TLR7 (2007) (0)
Methods for sequencing synthetic oligonucleotides containing non-phosphodiester linkages between nucleotides (1995) (0)
The role of p53 and p21 in cancer therapy with MDM2 inhibitor. (2004) (0)
MDM2 is a direct, p53-independent, negative regulator of p21 (2004) (0)
Synthesis of dimer blocks and their use to assemble oligonucleotides (1994) (0)
Su.50. A Toll-like Receptor Antagonist Prevents Development of IL-23-induced Psoriasis-like Dermal Changes in Mice (2008) (0)
Har Gobind Khorana (1922–2011): Pioneer of “Chemical Biology” (2012) (0)
Therapeutic anti-HIV oligonucleotide and drug (1993) (0)
IMPROVED SYNTHESIS OF OLIGONUCLEOTIDE METHYLPHOSPHONATE ANALOGS (1996) (0)
Olionukleotidalkylphosphonate and - phosphonothioate (1994) (0)
New synthons for stereoselective Oligonuklodsynthese (1996) (0)
Antitumor activity of a synthetic agonist of TLR9 in preclinical lung cancer models. (2006) (0)
Self-Stabilized Oligonucleotides as Novel Antisense Agents (2017) (0)
Sustained long-term effect of a novel immunomodulatory oligonucleotide on airway hyperresponsiveness in a mouse model of allergic airway inflammation (2005) (0)
Cancer Therapy : Preclinical Toll-like Receptor 9 Agonist IMOCooperateswithCetuximab in KRas Mutant Colorectal and Pancreatic Cancers (2011) (0)
Oligonucleotides d'immunomodulation stabilises (2004) (0)
Method for modulation of gene expression with reduced immune stimulatory effect (1996) (0)
Reversal of allergic airway inflammation and airway hyperresponsiveness by second-generation immunomodulatory oligonucleotide agents containing novel RpG motifs (2004) (0)
Oligonucleotide alkyl phosphonates and -alquilfosfonotioatos. (1994) (0)
153. Third Generation Antisense Targeted to Double Homeobox Protein 4 (DUX4) Reduced DUX4 Expression and Improved Differentiation of FSHD Myoblasts (2016) (0)
TLR9 agonists enhance the efficacy of cancer vaccines (2008) (0)
Abstract A56: Intratumoral injection of IMO-2055, a novel Toll-like receptor 9 agonist, with ipilimumab induces a systemic tumor-specific immune response (2015) (0)
Branched oligonucleotides as pathogenhemmende means (1995) (0)
Antisense oligonucleotide analogues as therapeutic agents. (1990) (0)
S.108. Modulation of Toll-like Receptor 3 Expression with Antisense (2009) (0)
CHAPTER 5. Oligonucleotide-based Toll-like Receptor Antagonists and Therapeutic Applications (2019) (0)
A 11 Patent Number : 5 , 637 , 459 45 ) Date of Patent : Jun . 10 , 1997 (2017) (0)
N‐Pent‐4‐enoyl (PNT) Group as a Universal Nucleobase Protector: Applications in the Rapid and Facile Synthesis of Oligonucleotides, Analogues, and Conjugates. (1997) (0)
Nucleic acid drugs (2012) (0)
HYB 2055 – a second-generation immunomodulatory oligonucleotide containing CpR motifs potently reverses allergic airway inflammation and airway hyperresponsiveness in mouse models of established asthma (2004) (0)
2187 : Adenoviral E2F1 and Antisense MDM2 Sensitize Prostate Cancer Cells To Androgen Deprivation and Radiation (2006) (0)
In vivo delivery of third generation oligonucleotides targeting DUX4 using a new mouse model of FSHD (2017) (0)
Methods for sequencing synthetic oligonucleotides containing internucleotide phosphodiester bonds other. (1993) (0)
1126 : Antisense MDM2 Oligonucleotides Sensitize Androgen-Insensitive Human Prostate Cancer Cells To Androgen Deprivation In Vitro And In Vivo (2006) (0)
Oligonucleotide compounds immuno regulators (IRO) for modulating the immune response based Toll-like receptor (2006) (0)
Corrigendum to "Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman Primates". (2010) (0)
Cellular delivery system with cyclodextrin, for oligonucleotides (1995) (0)
Ion Exchange HPLC Analysis of Oligoribonucleotides and Chimeric Oligoribo‐oligodeoxyribonucleotides a (1992) (0)
Groupes de protection de bases et procede de synthese d'oligonucleotides (1998) (0)
Erratum: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Clinical Pharmacology and Therapeutics (1995) 58 (44-53) DOI: 10.1016/0009-9236(95)90071-3) (2011) (0)
Synthesis of Iodoalkylacylates and Their Use in the Preparation of S‐ Alkyl Phosphorothiolates. (1995) (0)
Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation. (1988) (0)
Abstract 18654: C/D Box Small Nucleolar RNAs of the 14q32 Noncoding RNA Gene Cluster Play an Important Role in Human Cardiovascular Disease (2016) (0)
Hybrid oligonuclotid phosphorothioates (1993) (0)
Cyclodextrinsystem for delivery of oligonucleotides to cells (1995) (0)
S.105. Modulation of Toll-like Receptors 7 and 9 Expression with Antisense for Potential Applications in Autoimmune and Inflammatory Diseases (2009) (0)
OR.53. Prevention and Treatment of Ovalbumin-induced Inflammation in Mice with Toll-like Receptor Antagonists (2008) (0)
Structure of duplex oligodeoxynucleotides using non radiative fluorescence resonance energy transfer (1991) (0)
Modulating the immunostimulatory activity of immunostimulatory oligonucleotide by chemical positional changes (2001) (0)
S.106. Studies of Toll-like Receptors 7 and 9 Antisense in a Preclinical Model of Colitis (2009) (0)
28 Synergistic antiproliferative effects of ionizing radiations with anti-epidermal growth factor receptor monoclonal antibody C225 and protein kinase a antisense oligonucleotide hyb 165 (1999) (0)
Responses via Separate Mechanisms Motif Regulates Trafficking and TLR Cutting Edge: The UNC93B1 Tyrosine-Based (2014) (0)
Abstract 15507: Inhibition of MEF2A Using 3rd Generation Antisense Enhances Neovascularization via Posttranscriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494 (2016) (0)
Subcutaneous efficacy testing of two antisense oligonucleotides, HYB0184 and HYB0286, in SCID-hu-PBL reconstituted HIV-infected SCID mice (1997) (0)
Agonists new toll-like receptor 3 and use procedures (2011) (0)
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sudhir Agrawal?

Sudhir Agrawal is affiliated with the following schools:

Sudhir Agrawal's Academic­Influence.com Rankings

Sudhir Agrawal's Degrees

Similar Degrees You Can Earn

Why Is Sudhir Agrawal Influential?

Sudhir Agrawal's Published Works

Published Works

What Schools Are Affiliated With Sudhir Agrawal?

Sudhir Agrawal's AcademicInfluence.com Rankings